These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24032045)

  • 21. Telbivudine for the treatment of chronic hepatitis B infection.
    Hartwell D; Jones J; Harris P; Cooper K
    Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis.
    Geng J; Bao H; Chen Y; Shi L; Geng J; Wang Q; Yu H
    Expert Rev Anti Infect Ther; 2020 Aug; 18(8):823-834. PubMed ID: 32329638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.
    Xing T; Xu H; Cao L; Ye M
    PLoS One; 2017; 12(1):e0169444. PubMed ID: 28107377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients.
    Dienstag JL; Wei LJ; Xu D; Kreter B
    Clin Drug Investig; 2007; 27(1):35-49. PubMed ID: 17177578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Entecavir versus lamivudine for the treatment of chronic hepatitis B: a systematic review.
    Liang J; Tang YF; Wu FS; Deng X
    Pharmazie; 2012 Nov; 67(11):883-90. PubMed ID: 23210236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment efficacy of clevudine, entecavir and lamivudine in treatment-naive patients with HBeAg-positive chronic hepatitis B].
    Bae SH; Baek YH; Lee SW; Han SY
    Korean J Gastroenterol; 2010 Dec; 56(6):365-72. PubMed ID: 21173560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis.
    Zhao P; Liu W; Zhao J; Guan Q
    Virol J; 2011 Feb; 8():75. PubMed ID: 21342505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study.
    Tsai MC; Chen CH; Hung CH; Lee CM; Chiu KW; Wang JH; Lu SN; Tseng PL; Chang KC; Yen YH; Hu TH
    Clin Microbiol Infect; 2014 Feb; 20(2):O90-O100. PubMed ID: 23659493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
    Lü W; Yang HH; Fan YM; Li T; Zhang LF; Mui C; Fan HW; Zhou BT; Liu ZY; Ng H; Liu XQ
    Chin Med J (Engl); 2013 Jun; 126(12):2333-6. PubMed ID: 23786949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telbivudine in the treatment of chronic hepatitis B.
    Nash K
    Adv Ther; 2009 Feb; 26(2):155-69. PubMed ID: 19225726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
    Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
    Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine.
    Cai S; Cao J; Yu T; Xia M; Peng J
    Medicine (Baltimore); 2017 Jun; 96(22):e7021. PubMed ID: 28562554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
    Shi H; Han Z; Liu J; Xue J; Zhang S; Zhu Z; Xia J; Huang M
    Med Sci Monit; 2017 Nov; 23():5230-5236. PubMed ID: 29095799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C.
    Xu JH; Wang S; Zhang DZ; Yu YY; Si CW; Zeng Z; Xu ZN; Li J; Mao Q; Tang H; Sheng JF; Chen XY; Ning Q; Shi GF; Xie Q; Zhang XQ; Dai J
    World J Clin Cases; 2022 Oct; 10(28):10085-10096. PubMed ID: 36246814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B.
    Rivkin A
    Drugs Today (Barc); 2007 Apr; 43(4):201-20. PubMed ID: 17460784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.